Oncolytic Herpes simplex virus expressing yeast cytosine deaminase: Relationship between viral replication, transgene expression, prodrug bioactivation

Cancer Gene Therapy

Volumn 19, Issue 3, 2012, Pages 160-170

  Yamada, S ^a   Kuroda, T ^a   Fuchs, B C ^a   He, X ^a   Supko, J G ^a   Schmitt, A ^a   McGinn, C M ^a   Lanuti, M ^a   Tanabe, K K ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

cytosine deaminase; HSV 1; pharmacokinetics; viral oncolysis

Indexed keywords

CONDITIONALLY REPLICATING HERPES SIMPLEX VIRUS 1; CYTOSINE DEAMINASE; FLUCYTOSINE; FLUOROURACIL; GENOMIC DNA; ONCOLYTIC HERPES VIRUS; PRODRUG; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG POTENTIATION; DRUG TRANSFORMATION; DRUG TUMOR LEVEL; ENZYME PRODRUG THERAPY; GENE DOSAGE; GENE EXPRESSION; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; TRANSGENE; TUMOR CELL; VIRUS REPLICATION;

ANIMALIA; HUMAN HERPESVIRUS 1; SIMPLEXVIRUS;

EID: 84857115098     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2011.70     Document Type: Article

References (45)

1. Parato KA, Senger D, Forsyth PA, Bell JC. Recent progress in the battle between oncolytic viruses and tumours. Nat Rev Cancer 2005; 5: 965-976. (Pubitemid 41766784)
2. Cattaneo R, Miest T, Shashkova EV, Barry MA. Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded. Nat Rev Microbiol 2008; 6: 529-540. (Pubitemid 351850977)
3. Reid T, Galanis E, Abbruzzese J, Sze D, Wein LM, Andrews J et al. Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints. Cancer Res 2002; 62: 6070-6079. (Pubitemid 35244455)
4. Geevarghese SK, Geller DA, de Haan HA, Hörer M, Knoll AE, Mescheder A et al. Phase I/II study of oncolytic herpes simplex virus NV1020 in patients with extensively pretreated refractory colorectal cancer metastatic to the liver. Hum Gene Ther 2010; 21: 1119-1128.
5. Park BH, Hwang T, Liu TC, Sze DY, Kim JS, Kwon HC et al. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. Lancet Oncol 2008; 9: 533-542.
6. Senzer NN, Kaufman HL, Amatruda T, Nemunaitis M, Reid T, Daniels G et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol 2009; 27: 5763-5771.
7. Fong Y, Kim T, Bhargava A, Schwartz L, Brown K, Brody L et al. A herpes oncolytic virus can be delivered via the vasculature to produce biologic changes in human colorectal cancer. Mol Ther 2009; 17: 389-394.
8. Heise C, Sampson-Johannes A, Williams A, McCormick F, Von Hoff DD, Kirn DH. ONYX-015, an E1B geneattenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med 1997; 3: 639-645. (Pubitemid 27264973)
9. Khuri FR, Nemunaitis J, Ganly I, Arseneau J, Tannock IF, Romel L et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 2000; 6: 879-885. (Pubitemid 30644745)
10. Chase M, Chung R, Chiocca EA. An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy. Nat Biotech 1998; 16: 444-448. (Pubitemid 28211196)
11. Pawlik TM, Nakamura H, Mullen JT, Kasuya H, Yoon SS, Chandrasekhar S et al. Prodrug bioactivation and oncolysis of diffuse liver metastases by a herpes simplex virus 1 mutant that expresses the CYP2B1 transgene. Cancer 2002; 95: 1171-1181. (Pubitemid 34925371)
12. Tyminski E, Leroy S, Terada K, Finkelstein DM, Hyatt JL, Danks MK et al. Brain tumor oncolysis with replicationconditional herpes simplex virus type 1 expressing the prodrug-activating genes, CYP2B1 and secreted human intestinal carboxylesterase, in combination with cyclophosphamide and irinotecan. Cancer Res 2005; 65: 6850-6857. (Pubitemid 41060724)
13. Nakamura H, Mullen JT, Chandrasekhar S, Pawlik TM, Yoon SS, Tanabe KK. Multimodality therapy with a replication-conditional herpes simplex virus 1 mutant that expresses yeast cytosine deaminase for intratumoral conversion of 5-fluorocytosine to 5-fluorouracil. Cancer Res 2001; 61: 5447-5452. (Pubitemid 32694925)
14. Freeman SM, Abboud CN, Whartenby KA, Packman CH, Koeplin DS, Moolten FL et al. The 'bystander effect': tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 1993; 53: 5274-5283. (Pubitemid 23333399)
15. McCart JA, Puhlmann M, Lee J, Hu Y, Libutti SK, Alexander HR et al. Complex interactions between the replicating oncolytic effect and the enzyme/prodrug effect of vaccinia-mediated tumor regression. Gene Ther 2000; 7: 1217-1223. (Pubitemid 30488768)
16. Aghi M, Rabkin S, Martuza RL. Effect of chemotherapyinduced DNA repair on oncolytic herpes simplex viral replication. J Natl Cancer Inst 2006; 98: 38-50. (Pubitemid 43057091)
17. Carroll NM, Chiocca EA, Tanabe KK. The effect of ganciclovir on herpes simlex virus-mediated oncolysis. J Surg Res 1997; 69: 413-417. (Pubitemid 27317891)
18. Simpson GR, Han Z, Liu B, Wang Y, Campbell G, Coffin RS. Combination of a fusogenic glycoprotein, prodrug activation, and oncolytic herpes simplex virus for enhanced local tumor control. Cancer Res 2006; 66: 4835-4842.
19. Guffey MB, Parker JN, Luckett Jr WS, Gillespie GY, Meleth S, Whitley RJ et al. Engineered herpes simplex virus expressing bacterial cytosine deaminase for experimental therapy of brain tumors. Cancer Gene Ther 2007; 14: 45-56. (Pubitemid 44952233)
20. Foloppe J, Kintz J, Futin N, Findeli A, Cordier P, Schlesinger Y et al. Targeted delivery of a suicide gene to human colorectal tumors by a conditionally replicating vaccinia virus. Gene Ther 2008; 15: 1361-1371.
21. Kuroda T, Martuza RL, Todo T, Rabkin SD. Flip-Flop HSV-BAC: bacterial artificial chromosome based system for rapid generation of recombinant herpes simplex virus vectors using two independent site-specific recombinases. BMC Biotechnol 2006; 6: 40.
22. Erbs P, Regulier E, Kintz J, Leroy P, Poitevin Y, Exinger F et al. In vivo cancer gene therapy by adenovirus-mediated transfer of a bifunctional yeast cytosine deaminase/uracil phosphoribosyltransferase fusion gene. Cancer Res 2000; 60: 3813-3822. (Pubitemid 32204573)
23. Koyama F, Sawada H, Hirao T, Fujii H, Hamada H, Nakano H. Combined suicide gene therapy for human colon cancer cells using adenovirus-mediated transfer of escherichia coli cytosine deaminase gene and Escherichia coli uracil phosphoribosyltransferase gene with 5-fluorocytosine. Cancer Gene Ther 2000; 7: 1015-1022. (Pubitemid 30483481)
24. Chung-Faye GA, Chen MJ, Green NK, Burton A, Anderson D, Mautner V et al. In vivo gene therapy for colon cancer using adenovirus-mediated, transfer of the fusion gene cytosine deaminase and uracil phosphoribosyltransferase. Gene Ther 2001; 8: 1547-1554. (Pubitemid 33061893)
25. Kuroda T, Rabkin SD, Martuza RL. Effective treatment of tumors with strong beta-catenin/T-cell factor activity by transcriptionally targeted oncolytic herpes simplex virus vector. Cancer Res 2006; 66: 10127-10135. (Pubitemid 44672067)
26. Pisano R, Breda M, Grassi S, James CA. Hydrophilic interaction liquid chromatography-APCI-mass spectrometry determination of 5-fluorouracil in plasma and tissues. J Pharm Biomed Anal 2005; 38: 738-745. (Pubitemid 40835574)
27. Sabatini L, Barbieri A, Tosi M, Violante FS. A new highperformance liquid chromatographic/electrospray ionization tandem mass spectrometric method for the simultaneous determination of cyclophosphamide, methotrexate and 5-fluorouracil as markers of surface contamination for occupational exposure monitoring. J Mass Spectrom 2005; 40: 669-674. (Pubitemid 40733325)
28. Shah VP, Midha KK, Findlay JW, Hill HM, Hulse JD, McGilveray IJ et al. Bioanalytical method validation-a revisit with a decade of progress. Pharm Res 2000; 17: 1551-1557. (Pubitemid 32217566)
29. Pawlik TM, Nakamura H, Yoon SS, Mullen JT, Chandrasekhar S, Chiocca EA et al. Oncolysis of diffuse hepatocellular carcinoma by intravascular administration of a replication-competent, genetically engineered herpesvirus. Cancer Res 2000; 60: 2790-2795. (Pubitemid 30395793)
30. Chahlavi A, Todo T, Martuza RL, Rabkin SD. Replicationcompetent herpes simplex virus vector G207 and cisplatin combination therapy for head and neck squamous cell carcinoma. Neoplasia 1999; 1: 162-169.
31. Toyoizumi T, Mick R, Abbas AE, Kang EH, Kaiser LR, Molnar-Kimber KL. Combined therapy with chemotherapeutic agents and herpes simplex virus type 1 ICP34. 5 mutant (HSV-1716) in human non-small cell lung cancer. Hum Gene Ther 1999; 10: 3013-3029.
32. Post DE, Fulci G, Chiocca EA, Van Meir EG. Replicative oncolytic herpes simplex viruses in combination cancer therapies. Curr Gene Ther 2004; 4: 41-51. (Pubitemid 38854945)
33. Nakano K, Todo T, Zhao G, Yamaguchi K, Kuroki S, Cohen JB et al. Enhanced efficacy of conditionally replicating herpes simplex virus (G207) combined with 5-fluorouracil and surgical resection in peritoneal cancer dissemination models. J Gene Med 2005; 7: 638-648. (Pubitemid 40744530)
34. Gutermann A, Mayer E, von Dehn-Rothfelser K, Breidenstein C, Weber M, Muench M et al. Efficacy of oncolytic herpesvirus NV1020 can be enhanced by combination with chemotherapeutics in colon carcinoma cells. Hum Gene Ther 2006; 17: 1241-1253. (Pubitemid 44975140)
35. Petrowsky H, Roberts GD, Kooby DA, Burt BM, Bennett JJ, Delman KA et al. Functional interaction between fluorodeoxyuridine-induced cellular alterations and replication of a ribonucleotide reductase-negative herpes simplex virus. J Virol 2001; 75: 7050-7058. (Pubitemid 32641592)
36. Eisenberg DP, Adusumilli PS, Hendershott KJ, Yu Z, Mullerad M, Chan MK et al. 5-fluorouracil and gemcitabine potentiate the efficacy of oncolytic herpes viral gene therapy in the treatment of pancreatic cancer. J Gastrointest Surg 2005; 9: 1068-1077; discussion 77-79.
37. Adusumilli PS, Chan MK, Chun YS, Hezel M, Chou TC, Rusch VW et al. Cisplatin-induced GADD34 upregulation potentiates oncolytic viral therapy in the treatment of malignant pleural mesothelioma. Cancer Biol Ther 2006; 5: 48-53. (Pubitemid 43234977)
38. Weissleder R, Moore A, Mahmood U, Bhorade R, Benveniste H, Chiocca EA et al. In vivo magnetic resonance imaging of transgene expression. Nature Med 2000; 6: 351-355.
39. Jacobs A, Tjuvajev JG, Dubrovin M, Akhurst T, Balatoni J, Beattie B et al. Positron emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo. Cancer Res 2001; 61: 2983-2995. (Pubitemid 32691944)
40. Kuruppu D, Brownell AL, Zhu A, Yu M, Wang X, Kulu Y et al. Positron emission tomography of herpes simplex virus 1. oncolysis. Cancer Res 2007; 67: 3295-3300. (Pubitemid 46724868)
41. Gade TP, Koutcher JA, SpeesWM, Beattie BJ, Ponomarev V, Doubrovin M et al. Imaging transgene activity in vivo. Cancer Res 2008; 68: 2878-2884. (Pubitemid 351556287)
42. Harvey BG, Maroni J, O'Donoghue KA, Chu KW, Muscat JC, Pippo AL et al. Safety of local delivery of lowand intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of morbid conditions. Hum Gene Ther 2002; 13: 15-63. (Pubitemid 34075172)
43. Conrad C, Miller CR, Ji Y, Gomez-Manzano C, Bharara S, McMurray JS et al. Delta24-hyCD adenovirus suppresses glioma growth in vivo by combining oncolysis and chemosensitization. Cancer Gene Ther 2005; 12: 284-294. (Pubitemid 40315188)
44. Chang DY, Yoo SW, Hong Y, Kim S, Kim SJ, Yoon SH et al. The growth of brain tumors can be suppressed by multiple transplantation of mesenchymal stem cells expressing cytosine deaminase. Int J Cancer 2010; 127: 1975-1983.
45. Dias JD, Liikanen I, Guse K, Foloppe J, Sloniecka M, Diaconu I et al. Targeted chemotherapy for head and neck cancer with a chimeric oncolytic adenovirus coding for bifunctional suicide protein FCU1. Clin Cancer Res 2010; 16: 2540-2549.